Centrala begrepp
The Oncotype 21-gene breast recurrence score is a validated predictive biomarker for chemotherapy benefit in ER-positive/HER2-negative breast cancer across various ethnic groups.
Sammanfattning
The study validates the Oncotype 21-gene breast recurrence score as a predictive biomarker for chemotherapy benefit in women with ER-positive/HER2-negative breast cancer across different ethnic groups.
TOPLINE:
- Study validates Oncotype 21-gene breast recurrence score.
- Predictive biomarker for adjuvant chemotherapy benefit.
- Focus on women with ER-positive/HER2-negative breast cancer.
METHODOLOGY:
- Oncotype 21-gene score used for treatment decisions.
- Aimed to verify accuracy in underrepresented racial/ethnic groups.
- Analyzed data from women with stages I-II breast cancer.
- Evaluated impact on breast cancer death rates.
TAKEAWAY:
- Chemotherapy use varied among different ethnic groups.
- Risk for breast cancer deaths reduced with chemotherapy.
- No improvement in breast cancer mortality in Asian/Pacific Islander women.
- Lower potential cutoff for recommending chemotherapy in certain groups.
IN PRACTICE:
- Study clinically validated recurrence score as a predictive biomarker.
- Prospective trials recommended to confirm findings.
SOURCE:
- Led by Hsiao-Ching Huang, MPH, PhD.
- Published in the Journal of the National Comprehensive Cancer Network.
LIMITATIONS:
- Retrospective design with potential confounding variables.
- Lack of data on adjuvant endocrine therapy use.
- Incomplete information on chemotherapy in the SEER registry.
- Unknown HER2 status for patients before 2010.
DISCLOSURES:
- Supported by AbbVie Fellowship and National Cancer Institute.
- Some authors received financial support outside this work.
Statistik
"Of the 73,363 women included, 8.2% were Asian/Pacific Islander, 7.8% were non-Hispanic Black, 9.1% were Hispanic, and 74.9% were non-Hispanic White."
"Use of chemotherapy was significantly higher in non-Hispanic Black women (22.45%) than in Asian/Pacific Islander (20.87%), Hispanic (20.31%), and non-Hispanic White (19.13%) women (P < .0001)."
"The risk for breast cancer deaths was significantly reduced with chemotherapy in non-Hispanic Black (hazard ratio [HR], 0.70), Hispanic (HR, 0.38), and non-Hispanic White women (HR, 0.75)."
"Chemotherapy use did not improve breast cancer mortality in Asian/Pacific Islander women overall (HR, 0.67; 95% CI, 0.42-1.07)."
Citat
"this study clinically validated [recurrence score] as a predictive biomarker in non-Hispanic Black, Hispanic, and non-Hispanic White women"